Last updated: February 4, 2026
What are the key allegations and claims in this case?
Neurocrine Biosciences filed a patent infringement lawsuit against Crystal Pharmaceutical (Suzhou) Co., Ltd. on April 13, 2021, in the U.S. District Court for the District of Delaware. The complaint asserts that Crystal Pharmaceutical infringed U.S. Patent Nos. 9,877,342; 10,349,735; and 10,930,363. These patents cover compounds and methods related to neuropeptide receptor modulators targeted in neurological and psychiatric disorders.
The plaintiff alleges Crystal Pharmaceutical manufactured, used, sold, or offered for sale compounds in the U.S. that infringe these patents. The core claim centers on Crystal's purported unauthorized development of drug formulations similar to Neurocrine’s offerings, particularly related to controls on compounds used in treatments for conditions like tardive dyskinesia and schizophrenia.
What is the procedural posture?
- Filing date: April 13, 2021
- Jurisdiction: U.S. District Court for the District of Delaware
- Defendant: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Current status: As of December 2022, the case remains in early stages. No final summary judgment or trial date has been scheduled. Both parties filed preliminary motions, including requests for claim construction hearings.
What legal issues are contested?
- Patent validity: Crystal Pharmaceutical challenges the validity of the asserted patents, citing obviousness, anticipation, and patentable subject matter concerns.
- Infringement: Neurocrine alleges direct infringement through Crystal Pharmaceutical’s manufacturing of compounds that fall within the scope of the patents.
- Subject matter jurisdiction: The case involves questions about whether the patents cover methods or compositions that would be patentable under U.S. law.
- Damages and injunctive relief: Neurocrine seeks declaratory judgments of infringement and monetary damages, along with injunctive relief to prevent further sales.
What are the legal strategies and potential implications?
- Patent defense challenges: Crystal Pharmaceutical likely will file motions to dismiss or for summary judgment on patent validity, focusing on prior art and obviousness.
- Claim construction: Both sides are expected to argue over the scope and interpretation of key patent terms. Clarification could influence infringement and validity determinations significantly.
- Market impact: Admission of infringement would threaten Crystal’s ability to sell, manufacture, or develop competing compounds in the U.S.
- Patent strength: The patents are relatively recent, with the earliest filed in 2017, which suggests they have a shorter remaining term, possibly affecting damages calculations and settlement dynamics.
What is the significance of this case?
This lawsuit demonstrates ongoing patent enforcement efforts by Neurocrine Biosciences around neuropeptide receptor modulators. It emphasizes the importance of patent clarity and strategic claim drafting to deter infringement and defend market share. It also reveals industry tensions in developing complex neuropharmacology therapeutics, with patent disputes serving as a barrier to generic or competing entrants.
Key Takeaways
- The case reflects Neurocrine’s active patent protection in neurological therapeutics.
- Crystal Pharmaceutical challenges patent validity, a typical defense in biosciences litigation.
- The case’s outcome may influence patent stability and market access for neuropeptide-based drugs.
- Claim construction will play a crucial role in defining infringement scope.
- The litigation timeline remains uncertain, with preliminary motions likely over the next year.
FAQs
1. What patents are involved in this lawsuit?
Three patents are involved: U.S. Patent Nos. 9,877,342; 10,349,735; and 10,930,363. They cover compounds and methods related to neuropeptide receptor modulators used in neuropsychiatric treatment.
2. What defenses might Crystal Pharmaceutical pursue?
Crystal Pharmaceutical may argue the patents are invalid due to obviousness or anticipation, and challenge the scope of patent claims during claim construction.
3. How could this case affect market competitors?
A finding of infringement could restrict Crystal Pharmaceutical’s ability to sell or develop similar compounds in the U.S. until patent validity is either upheld or invalidated.
4. What is the role of claim construction in this litigation?
Claim construction interprets patent language, determining scope and influencing whether Crystal's compounds infringe or the patents are valid.
5. When might a resolution occur?
Litigation is in early stages; resolution through settlement, summary judgment, or trial could extend into 2024, depending on the pace of motions and discovery.
References
[1] U.S. District Court for the District of Delaware, Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd., Case No. 1:21-cv-01464, 2021.
